Oleg Nodelman - Nuvation Bio Director
| NUVB Stock | USD 2.88 0.26 9.92% |
Insider
Oleg Nodelman is Director of Nuvation Bio since 2021.
| Age | 44 |
| Tenure | 3 years |
| Address | 1500 Broadway, New York, NY, United States, 10036 |
| Phone | 332 208 6102 |
| Web | https://www.nuvationbio.com |
Oleg Nodelman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Oleg Nodelman against Nuvation Bio stock is an integral part of due diligence when investing in Nuvation Bio. Oleg Nodelman insider activity provides valuable insight into whether Nuvation Bio is net buyers or sellers over its current business cycle. Note, Nuvation Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nuvation Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Oleg Nodelman over a year ago Purchase by Oleg Nodelman of 5143000 shares of Nuvation Bio | ||
Oleg Nodelman over a year ago Purchase by Oleg Nodelman of 5143000 shares of Nuvation Bio |
Nuvation Bio Management Efficiency
The company has return on total asset (ROA) of (0.1398) % which means that it has lost $0.1398 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9554) %, meaning that it created substantial loss on money invested by shareholders. Nuvation Bio's management efficiency ratios could be used to measure how well Nuvation Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of November 11, 2024, Return On Tangible Assets is expected to decline to -0.13. The current year's Return On Capital Employed is expected to grow to -0.16. At present, Nuvation Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 2.4 M, whereas Total Current Assets are forecasted to decline to about 439.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Karl MD | Achilles Therapeutics PLC | 57 | |
| Robert Coutts | Achilles Therapeutics PLC | 40 | |
| Uri MD | Assembly Biosciences | 52 | |
| Sandeep MD | Instil Bio | 55 | |
| James Brady | Spero Therapeutics | N/A | |
| MBA MD | Spero Therapeutics | 43 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| MD FACP | NextCure | 71 | |
| Bronson Crouch | Instil Bio | 51 | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| Timothy Mayer | NextCure | 59 | |
| Sergio Quezada | Achilles Therapeutics PLC | 49 | |
| Nicole White | Assembly Biosciences | N/A | |
| Mark Dudley | Instil Bio | N/A | |
| Angela MD | Spero Therapeutics | N/A | |
| Christopher Ogden | CytomX Therapeutics | 40 | |
| Iraj Ali | Achilles Therapeutics PLC | 49 | |
| Lieping MD | NextCure | 67 | |
| Hoyoung MD | CytomX Therapeutics | 55 | |
| MBA BS | CytomX Therapeutics | 45 | |
Management Performance
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.14 |
Nuvation Bio Leadership Team
Elected by the shareholders, the Nuvation Bio's board of directors comprises two types of representatives: Nuvation Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nuvation. The board's role is to monitor Nuvation Bio's management team and ensure that shareholders' interests are well served. Nuvation Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nuvation Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| W Vernon, Independent Director | ||
| David Hung, President, Chief Executive Officer, Founder, Director | ||
| Michelle Doig, Independent Director | ||
| Gary Hattersley, Chief Scientific Officer | ||
| Moses Makunje, Principal Officer | ||
| Robert Bazemore, Independent Director | ||
| Jennifer Fox, Chief Financial Officer | ||
| Kerry Wentworth, Chief Officer | ||
| Daniel Welch, Independent Chair of the Board | ||
| Colleen Sjogren, Chief Officer | ||
| David Hanley, Chief Technical Operations Officer | ||
| Thomas Templeman, Senior Vice President - Pharmaceutical Operations and Quality | ||
| Moses CPA, VP Officer | ||
| Stacy Markel, Senior Vice President - Human Resources | ||
| Kathryn Falberg, Independent Director | ||
| Oleg Nodelman, Director | ||
| Kim Blickenstaff, Independent Director | ||
| Stephen Dang, VP Secretary | ||
| Junyuan Wang, CEO Director | ||
| Philippe Sauvage, Chief Officer | ||
| Sergey Yurasov, Chief Medical Officer | ||
| David MD, President, Founder |
Nuvation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nuvation Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.14 | ||||
| Operating Margin | (66.16) % | ||||
| Current Valuation | 431.37 M | ||||
| Shares Outstanding | 335.57 M | ||||
| Shares Owned By Insiders | 26.86 % | ||||
| Shares Owned By Institutions | 44.10 % | ||||
| Number Of Shares Shorted | 9.97 M | ||||
| Price To Book | 1.93 X | ||||
| Price To Sales | 448.34 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Nuvation Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Nuvation Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nuvation Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nuvation Bio Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvation Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Nuvation Stock refer to our How to Trade Nuvation Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvation Bio. If investors know Nuvation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.18) | Revenue Per Share 0.009 | Return On Assets (0.14) | Return On Equity (0.96) |
The market value of Nuvation Bio is measured differently than its book value, which is the value of Nuvation that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvation Bio's value that differs from its market value or its book value, called intrinsic value, which is Nuvation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvation Bio's market value can be influenced by many factors that don't directly affect Nuvation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.